HIGHFDA DRUG

Cipla Recalls Cinacalcet Hydrochloride Tablets Over Impurity Risk

Cipla USA, Inc. recalled 63,504 bottles of Cinacalcet Hydrochloride Tablets on November 14, 2025. The recall results from a nitrosamine impurity, N-nitroso-cinacalcet, exceeding acceptable daily intake limits. Consumers should stop using the tablets immediately and contact healthcare providers for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
November 14, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
November 14, 2025
Hazard Level
HIGH
Brands
CINACALCET, Cipla USA Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
CINACALCET, Cipla USA Inc.
Product type
Cinacalcet Hydrochloride Tablets
Model numbers
Lot, expiry: Lot 4PB0109, exp 1/31/2026, Lot 5PB0172, exp 1/31/2027
UPC codes
69097-410, 69097-411, 69097-412, 69097-410-02, 69097-411-02, 69097-412-02
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    November 14, 2025

  2. Reported by FDA DRUG

    December 17, 2025

  3. RecallRadar source check

    December 24, 2025

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Cipla USA, Inc. or your healthcare provider for guidance. Notification method: Letter

About This Product

Cinacalcet Hydrochloride Tablets are used to treat conditions related to elevated parathyroid hormone levels, often prescribed for patients with chronic kidney disease or hyperparathyroidism. Patients buy these tablets for their potential to manage calcium and phosphorus levels in the body effectively.

Why This Is Dangerous

The recall is due to the presence of N-nitroso-cinacalcet, a nitrosamine impurity, which exceeds acceptable levels. Nitrosamines can form during the manufacturing process and have been linked to cancer risk.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers must stop using the product immediately due to the potential health risks associated with nitrosamine exposure. This may lead to inconvenience as patients seek alternatives or consult their healthcare providers.

Practical Guidance

How to identify if yours is affected

  1. Check the bottle for the lot numbers: 4PB0109 or 5PB0172.
  2. Verify the expiry dates: 1/31/2026 or 1/31/2027.
  3. If you have purchased Cinacalcet Hydrochloride Tablets, confirm your product matches the recalled lots.

Where to find product info

Lot numbers and expiration dates are typically printed on the label or the bottom of the bottle.

What timeline to expect

Expect a refund or replacement to be processed within 4-6 weeks after returning the product.

If the manufacturer is unresponsive

  • Keep records of your communication with the company.
  • Reach out again, or escalate your inquiry to a consumer protection agency.

How to prevent similar issues

  • Always check for recalls before using prescription medications.
  • Consult your physician about potential alternatives if a recall occurs.

Documentation advice

Document your purchase by keeping receipts and any correspondence with the manufacturer regarding the recall.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recall involves Cinacalcet Hydrochloride Tablets, 30 mg, sold in bottles of 30 tablets. The affected lot numbers are 4PB0109 (expiry 1/31/2026) and 5PB0172 (expiry 1/31/2027). These tablets were distributed nationwide in the U.S.

Key Facts

  • Recall date: November 14, 2025
  • Quantity recalled: 63,504 bottles
  • Affected lot numbers: 4PB0109, 5PB0172
  • Health risk: Nitrosamine impurity
  • Immediate action required

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product TypeCinacalcet Hydrochloride Tablets
Sold At
Multiple Retailers

Product Details

Model Numbers
Lot
expiry: Lot 4PB0109
exp 1/31/2026
Lot 5PB0172
exp 1/31/2027
UPC Codes
69097-410
69097-411
69097-412
+3 more
Affected States
ALL
Report Date
December 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Cipla USA Recalls Lanthanum Carbonate Tablets Over Stability Issues

Cipla USA recalled 1,180 boxes of Lanthanum Carbonate chewable tablets on October 24, 2025. The recall follows a failure to meet stability specifications for hardness tests. Consumers and healthcare providers must stop using the product immediately.

LANTHANUM CARBONATE
Failed stability
Read more